Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients.

"data availability statement the scrna-seq data have been deposited in gene expression omnibus (geo) with accession number: gse234241 author contributions alex s genshaft and adam j gehring wrote the manuscript. a cluster of regulatory t cells ( cd3 ctla4 il2rb and foxp3 ) was unique to the seq-well s3 dataset when compared to data obtained using the 10 x 3? data availability statement the scrna-seq data have been deposited in gene expression omnibus (geo) with accession number: gse234241"

"CONFLICTS OF INTEREST Nádia Conceição-Neto is employed by Janssen Pharmaceutica NV. Jordan Feld consults and received grants from Arbtus, AbbVie, Gilead, GlaxoSmithKline, Janssen, Roche, and Vir. He received grants from Eiger and Enanta. Raymond T. Chung received grants from AbbVie, Boehringer, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck, and Roche. Robert J. de Knegt consults, is on the speakers' bureau, and received grants from AbbVie, Echosens, and Gilead. He consults and received grants from Bristol Myers Squibb, Janssen, Medtronic, and Roche. He consults for Merck and Norgine. He received grants from GlaxoSmithKline and Phillips. Henry L.A. Janssen consults and received grants from Arbutus, Gilead, GlaxoSmithKline, Janssen, Merck, Roche, and Vir. He consults for Aligos, Antios, Arena, Eiger, Enyo, Regulus, VBI Vaccines, and Viroclinics. He received grants from AbbVie, Arbutus, and Bristol Myers Squibb. Jeroen Aerssens owns stock in Johnson & Johnson. He is employed by Janssen. Jacques Bollekens consults, owns stock in, and holds intellectual property rights with Johnson & Johnson. He is employed by Janssen. Nir Hacohen consults and owns stock in DangerBio. He owns stock in Biontech. Georg M. Lauer consults for and received grants from Janssen. He consults for Altimmune, GlaxoSmithKline, and Roche. Andre Boonstra received grants from Fujirebio, Gilead, GlaxoSmithKline, and Janssen. Alex K. Shalek consults, advises, and owns stock in Cellarity, Dahlia Biosciences, Honeycomb Biotechnologies, Ochre Bio, Repertoire Immune Medicines, Relation Therapeutics, and Santa Ana Bio. He consults and received grants from Janssen. He consults for FL82, Hovione, Merck, Roche, and Third Rock Ventures. He received grants from Leo Pharma A/S and Novo Nordisk. Adam J. Gehring consults and received grants from BlueJay Therapeutics, Gilead, GlaxoSmithKline, Janssen Pharmaceuticals, Roche, and Vir Biotech. He consults for Assembly, Finich Therapeutics, SQ BioTech, Viron Therapeutics, and VBI Vaccines. The remaining authors have no conflicts to report."

"FUNDING INFORMATION This study was funded by Janssen Pharmaceuticals. Raymond T. Chung was supported by the Massachusetts General Hospital Research Scholars Program. Adam J. Gehring received support from The Toronto Centre for Liver Disease and Canada Foundation for Innovation. Alex K. Shalek receives funding from the NIH, Break Through Cancer, the Pew-Stewart Scholars Program, Foundation MIT, Wellcome Leap, the Bill & Melinda Gates Foundation, and the Moore Foundation."